两代磁共振引导聚焦超声系统治疗子宫肌瘤的临床性能比较
单中心回顾性比较两代MRgFUS系统治疗症状性子宫肌瘤:第二代系统在暗T2和亮T2肌瘤中均取得更高的无灌注体积比(暗T2 80% vs 46%,P=0.00002;亮T2 46% vs 32%,P=0.001),且第二代系统引入后未记录到住院、皮肤烧伤或重大不良事件。
要点
- 第二代MRgFUS系统较第一代显著提高暗T2肌瘤无灌注体积比(80% vs 46%,P=0.00002)。
- 第二代系统较第一代显著提高亮T2肌瘤无灌注体积比(46% vs 32%,P=0.001)。
- 第二代ExAblate 2100系统引入后未记录到住院、皮肤烧伤或重大不良事件。
诊断标准与关键数值
- 暗T2肌瘤无灌注体积比:第二代系统80% vs 第一代系统46%,P=0.00002。
- 亮T2肌瘤无灌注体积比:第二代系统46% vs 第一代系统32%,P=0.001。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
OBJECTIVES: The aim of this study was to evaluate the impact of technology improvements on the outcomes of magnetic resonance-guided focused ultrasound (MRgFUS) treatments of symptomatic uterine leiomyomas (uterine fibroids). The study compared ablation volumes and incidence of adverse events in patient groups treated with two generations of MRgFUS systems from a single vendor.
METHODS: The present study describes the results of a retrospective comparative study of two groups of women with symptomatic uterine leiomyomas who were clinically treated with MRgFUS at a single institution. Group 1 (n = 130) was treated using the first-generation system between March 2005 and December 2009. Group 2 (n = 71) was treated using the second-generation between December 2013 and September 2019.
RESULTS: The second-generation MRgFUS system resulted in significantly improved nonperfused volume ratios in both dark and bright T2 fibroid categories compared with the first-generation system (dark - 80% versus46 %, p = 0.00002 and bright - 46% versus 32%, p = 0.001). There have been no recorded hospital admissions, no skins burns, and no reported major adverse events since the introduction of this second-generation ExAblate 2100 system with advanced safety and treatment planning features.
CONCLUSION: This study has demonstrated that improvements to current MRgFUS technology resulted in significantly increased efficacy and patient safety of clinical treatments of patients with symptomatic uterine leiomyomas.
引用
- Browne JE, Gorny KR, Hangiandreou NJ, et al. Comparison of Clinical Performance Between Two Generations of Magnetic Resonance-guided Focused Ultrasound Systems in Treatments of Uterine Leiomyomas. Acad Radiol. 2020. PMID: 32631759. doi:10.1016/j.acra.2020.06.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。